Tulathromycin enhances humoral but not cellular immune response in pigs vaccinated against swine influenza.

Opis bibliograficzny

Tulathromycin enhances humoral but not cellular immune response in pigs vaccinated against swine influenza. [AUT.] POMORSKA-MÓL MAŁGORZATA, KWIT KRZYSZTOF, PEJSAK ZYGMUNT, CZYŻEWSKA-DORS EWELINA. Journal of Veterinary Pharmacology and Therapeutics. DOI: 10.1111/jvp.12742
Skopiowane!
Kliknij opis aby skopiować do schowka

Szczegóły publikacji

Rok:2019
Język:angielski
Charakter formalny:Artykuł w czasopismie
Typ MNiSW/MEiN:inne

Streszczenia

The effect of a standard, single dose therapy with tulathromycin was investigated on the postvaccinal humoral and cellular immune response in pigs vaccinated against swine influenza. Forty‐five pigs, divided into 3 groups, were used (control not vaccinated (C, n = 15), control vaccinated (CV, n = 15), and experimentally received tulathromycin (TUL, n = 15)). For vaccination of pigs, an inactivated, commercial vaccine was used. Pigs from TUL group received single dose of tulathromycin intramuscularly, at the recommended dose (2.5 mg/kg body weight). Pigs from TUL and CV groups were vaccinated at 8 and 10 weeks of age. The specific humoral and cellular immune response against swine influenza virus (SIV) was evaluated. The results of present study showed that humoral postvaccinal response after vaccination against SIV can be modulated by treatment with tulathromycin. In pigs from TUL group, the significantly higher titers of anti‐SIV‐specific antibodies were observed 4 and 6 weeks after booster dose of vaccine. Simultaneously, T‐cell‐mediated immune response against SIV was not affected by tulathromycin. Our recent study confirmed the importance of defining the modulatory activity of tulathromycin because of its influence on the immune response to vaccines. Since the antibodies against hemagglutinin are crucial for the protection against SIV, the present observations should prompt further studies on the practical significance of recent results in terms of clinical implications (postvaccinal protection) in the field conditions.

Identyfikatory

ISSN: 0140-7783
e-ISSN: 1365-2885
BPP ID: (7, 8520) wydawnictwo ciągłe #8520

Metryki

70,00
Punkty MNiSW/MEiN
0
Impact Factor
0
Index Copernicus
0
Punktacja wewnętrzna

Eksport cytowania

Wsparcie dla menedżerów bibliografii:
Ta strona wspiera automatyczny import do Zotero, Mendeley i EndNote. Użytkownicy z zainstalowanym rozszerzeniem przeglądarki mogą zapisać tę publikację jednym kliknięciem - ikona pojawi się automatycznie w pasku narzędzi przeglądarki.

Skopiowane!

Informacje dodatkowe

Status:przed korektą
Praca recenzowana:nie
Rekord utworzony:2 kwietnia 2025 01:21
Ostatnia aktualizacja:2 kwietnia 2025 01:21